The results of preclinical studies showed that it could effectively inhibit proliferation of crizotinib-sensitive or -resistant tumor cell lines, and ALK-positive crizotinib-sensitive or -resistant tumor growth in mouse models (data unpublished). The gene discussed is ALK; the disease is neoplasm.